Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

Alfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Francis Giles, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Jenny Shan, Srdan Verstovsek, Jorge Cortes

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

BACKGROUND. Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML. METHODS. Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m2 orally daily 5 days a week, every 4 to 6 weeks. RESULTS. Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toricities (12%). CONCLUSIONS. 9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.

Original languageEnglish (US)
Pages (from-to)1525-1529
Number of pages5
JournalCancer
Volume107
Issue number7
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

    Fingerprint

Keywords

  • 9-nitrocamptothecin
  • Chronic myelomonocytic leukemia
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Jabbour, E., Giles, F., Ravandi, F., Faderl, S., Pierce, S., Shan, J., Verstovsek, S., & Cortes, J. (2006). Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer, 107(7), 1525-1529. https://doi.org/10.1002/cncr.22186